The Center for Biosimilars® recaps the top stories for the week of June 17, 2019.
Transcript
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of June 17.
Number 5: During the 24th Congress of the European Hematology Association, researchers reported on findings from a phase 1 trial of Amgen’s proposed eculizumab biosimilar.
Number 4: At the European League Against Rheumatism’s Annual European Congress of Rheumatology, researchers said a biosimilar adalimumab has a “significant advantage” over the reference in terms of injection pain.
Number 3: Irish hospitals will be offered an incentive for each patient switched from brand-name Humira or Enbrel to a biosimilar option.
Number 2: A new study has found that switching among multiple biosimilar infliximab products was not associated with increased immunogenicity.
Number 1: A Canadian advisory council is recommending the use of biosimilars in a final report that lays out recommendations for how the country can create a single-payer public system for pharmaceutical coverage.
Finally, last week, our e-newsletter asked whether you think that anticancer biosimilars will have swifter US uptake than biosimilars that treat inflammatory diseases.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.